Dewpoint Therapeutics raises $60 mln
Summary
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A. Biomolecular condensates have long been known but historically understudied because they are difficult to analyze with traditional drug discovery methods like protein crystallography and biochemical activity assays. Nashat and Tony Hyman will be joined on the board by Dewpoint Chief Scientific Officer Mark Murcko, Srinivas Akkaraju of Samsara BioCapital, and Wei Li of 6 Dimensions Capital. Based in San Francisco, EcoR1 evaluates and selects extraordinary biotechnology companies that are pursuing the highest quality science and demonstrate strong business fundamentals. Based on its experience and in-depth understanding of the life science and technology industries, its long-term relationships with leading investors, and its world-class scientific advisory network, Alexandria Venture Investments is uniquely positioned to fund seed-, early-, and growth-stage companies.